Evaluation of the in vitro skin permeation of antiviral drugs from penciclovir 1% cream and acyclovir 5% cream used to treat herpes simplex virus infection
© Hasler-Nguyen et al; licensee BioMed Central Ltd. 2009
Received: 27 June 2008
Accepted: 02 April 2009
Published: 02 April 2009
Herpes simplex virus infection (HSV) is a common and ubiquitous infection of the skin which causes mucocutaneous lesions called cold sores (herpes labialis) or fever blisters. It is estimated that approximately 80% of the population worldwide are carriers of the Herpes simplex virus, approximately 40% suffer from recurrent recurrent infections. This study evaluates the in vitro skin permeation and penetration of penciclovir and acyclovir from commercialized creams for the treatment of herpes labialis (cold sores), using non viable excised human abdominal skin samples, which were exposed to 5 mg/cm2 of acyclovir 5% cream or penciclovir 1% cream.
After 24 h of cream application, excess cream was washed off and layers of stratum corneum were removed by successive tape stripping. Amounts of active ingredients having penetrated through the skin were measured, as well as the amounts in the washed-off cream, in skin strips and creams remaining in the skin. Molecular modelling was used to evaluate physico-chemical differences between the drugs. Western blot analysis enabled to determine whether the marker of basal cells keratin 5 could be detected in the various tape strips.
Application of penciclovir 1% cream yielded higher concentration of drug in the deeper layers of the epidermis as well as a higher drug flux through the skin. Molecular modelling showed two higher hydrophobic moieties for acyclovir. Presence of the basal cell marker keratin 5 was underscored in the deeper tape strips from the skin, giving evidence that both drugs can reach their target cells.
Penciclovir 1% cream has the tendency to facilitate the diffusion of the drug through the stratum corneum into the deeper epidermis layers, in which it could reach the target basal cells at effective therapeutical concentration. The small difference in the surface properties between both molecules might also contribute to favour the passage of penciclovir through the epidermis into the deeper basal cells.
Herpes simplex virus infection (HSV) is a common and ubiquitous infection of the skin which causes mucocutaneous lesions called cold sores (herpes labialis) or fever blisters. The vast majority of cold sores are due to herpes simplex virus type 1 (HSV-1). It is estimated that approximately 80% of the population worldwide are carriers of the Herpes simplex virus, approximately 40% suffer from recurrent infections [1, 2]. About 1% of sufferers have frequent, i.e. monthly outbreaks of the latent herpes infection. These infections last for 4 to 10 days and can extend up to 30 days in immunocompromised patients where lesions may develop extensive necrosis . Topical treatment with antiviral drugs like acyclovir and penciclovir is effective in shortening lesion duration and in relieving pain, as has been shown in large randomized, double-blind, vehicle controlled multi-centre clinical trials [1–4].
As the permeability properties of the stratum corneum remain unchanged after removal from the body, a good correlation has been observed between in vivo and in vitro experiments with the same drug [9–11]. Thus, in vitro diffusion through non viable human skin is a convenient experimental tool to explore permeation characteristics of a drug from its topical formulation.
The present study compared the in vitro skin distribution and permeation of two commercialized creams containing 1% penciclovir or 5% acyclovir, both containing approximately 40% propylene glycol. In vitro skin permeation was assessed using human skin mounted in Franz-type diffusion cells . Following topical application of 5 mg/cm2 cream on excised human skin, drug permeation into the receptor fluid of the diffusion chamber was measured after 24 h. At the end of the experiment drug levels in the remaining skin were determined after removal of the stratum corneum by tape stripping. Additionally, physico-chemical differences between the drugs were investigated by molecular modelling as this is a factor affecting dermal absorption .
Penciclovir cream 1% (10 mg/g penciclovir, Fenivir, Novartis Consumer Health, Switzerland) was provided in house and acyclovir cream 5% (50 mg/g acyclovir; Zovirax, GlaxoSmithKline, United Kingdom) was purchased from a Swiss pharmacy.
Penciclovir was provided in house and acyclovir was bought from Sigma Chemicals (Switzerland).
After securing the appropriate consent the ethical committee of the International Institute for the Advancement of Medicine (IIAM; United States) reviewed and approved our application for request of human tissue to be used in this study.
Full thickness human abdominal skin from 6 donors, which was taken at autopsy, was provided cryopreserved by IIAM. The skin was maintained frozen at -80°C. Prior to use, the skin was thawed and the subcutaneous tissue was carefully removed. The skin was dermatomed to 500 μm using a Wagner dermatome (model GB-231 Aesculap, Germany), which enabled us to obtain split thickness tissue constituted of the stratum corneum (10–20 μm), the epidermis (100 μm) and part of the dermis (1200 μm) [14, 15].
Test of skin integrity
The permeation of tritiated water was evaluated to determine the skin integrity as described by Bronaugh . Briefly, tritiated water (2.7 μCi/ml) was applied to the skin surface. After 30 min, the radiolabelled water was removed from the skin with cotton-wool tips. The receptor phase (2 ml) was taken in order to measure the amount of tritiated water (%) which permeated across the skin, using a liquid scintillation counter. Formulations were tested on skin samples having similar tritiated water permeation values. Less than 1% of the applied dose of tritiated water permeated through the skin.
Skin permeation is the diffusion of the drug across the skin layer into the receptor phase which represents blood vessels. It was measured using a static Franz diffusion cell of 1.75 cm2 for each skin sample exposed to the product to be tested at 5 mg/cm2 simulating in use conditions and in accordance to the test guideline OECD 428 .
Thawed human dermatomed skin samples were mounted horizontally on the Franz cells, dermis side down. The Franz cells were connected to a circulating water bath at 37°C, which yielded a tissue temperature of 32°C, comparable to the physiological temperature of the skin surface. The receptor phase of PBS pH 7.4 (phosphate buffered saline; 7.58 g/L Na2HPO4, 1.62 g/L NaH2PO4 and 4.4 g/L NaCl) contained within each diffusion cell (approximately 8 ml) was mixed using a magnetic stirring device to ensure appropriate homogenization of the released drug in the acceptor phase throughout the experiment. Samples of the receptor phase were collected at 24 h.
The skin penetration was determined by measuring the amount of drug residing in the various skin layers.
At the end of the 24 h after application skin samples were washed off with soapy water and cotton-wool tips. The top layer of the stratum corneum was removed with adhesive tape (3 M Scotch n° 550) and analyzed separately. Additional layers of the stratum corneum were removed by up to 12 consecutive adhesive tape strips.
Following collection of all strips, the first and the second strips were put into separate vials containing 10 ml of water. Strips 3 up to 7 were pooled in the same vial containing 20 ml of water. The remaining stripped skin was minced and placed into a vial containing 15 ml water. Mixtures were stirred overnight to ensure adequate extraction of the drug from the tape and the skin.
Penciclovir and acyclovir content in the various samples was measured by high performance liquid chromatography (Agilent HP 1100) on a Waters Spherisorb® 5 μm ODS2 (4.6 × 250 mm Analytical Cartridge PSS839540) phase column at 35°C using a 1 ml flow rate of the mobile phase of a mixture of methanol and 0.1 M pH 6.0 ammonium acetate buffer 1:10 (v:v) with UV detection at 254 nm. The sample was directly injected at a volume of 50 μl. Drug concentrations were determined from penciclovir or acyclovir standard curves between 10 and 50 ng/ml generated with the pure compounds solubilized in PBS at pH 7.4, which was the solvent used in the receptor phase. Maximal soluble concentration in this solvent was 0.9 mg/ml for penciclovir and 0.7 mg/ml for acyclovir. The retention time was respectively 6.7 min for penciclovir and 5.1 min for acyclovir. The limit of quantitation (LOQ) was 7 ng/ml for both drugs.
The characteristics of the penciclovir and acyclovir chemical structures were evaluated with an in house web based CHEMINFORMATICS system using the CORINA program. Generation and display of molecular surface properties enabled us to reveal those parts of the molecules which are involved in hydrophobic or hydrophilic interactions .
Western blot analysis
The skin sample from one donor was washed off with soapy water and cotton-wool tips 24 h after the cream application. The top layer of the stratum corneum was removed with adhesive tape (3 M Scotch n° 550) and analyzed separately. Additional layers of the stratum corneum were removed by up to 12 consecutive adhesive tape strips. Following collection of all strips, the first and the second strips were put into separate vials. Then pools of 3 to 4 strips were put in the same vial and the last strip was placed separately in another vial. A volume of 250 μl/tape strip of ice-cold lysis buffer (20 mM Tris-HCl; 2 mM EGTA; 2 mM EDTA; 30 mM NaF; 30 mM Na4O7P2; 2 mM Na3VO4; 1 mM [4-(2-Aminoethyl)benzenesulfonylfluoride] (AEBSF); 10 μg/ml leupeptin; 4 μg/ml aprotinin; 1% Triton X-100; pH 7.4) was added in the vial, which was left for 10 min on ice and then vortexed. Supernatants were collected and stored at -20°C overnight. Protein concentrations were measured by the BCA protein assay (Pierce).
Ten μl of protein samples corresponding to 3 μg of protein from tape strips lysat were separated by 10% SDS-PAGE and transferred to polyvinylidene difluoride membranes (Immobilon-P, Millipore, Bedford, MA). Membranes were blocked by incubation with Trisbuffered saline (50 mM Tris, 150 mM NaCl) containing 0.2% (v/v) Nonidet P-40 and 5% (w/v) nonfat dry milk for 30 min at room temperature. Membranes were probed overnight at 4°C with a monoclonal mouse anti-human Keratin 5 (Millipore) antibody (1:20,000) and then with secondary horseradish peroxidase-conjugated goat anti-human IgG (1:20,000) (Transduction Laboratories, Lexington, KY) for 1 h at room temperature. The membranes were washed three times with Tris-buffered saline containing 0.2% (v/v) Nonidet P-40, and the antigen-antibody complexes were detected by the Super Signal Substrate method (Pierce). Identified protein bands were detected using a video densitometer and ImageQuant software (Molecular Dynamics, Sunnyvale, CA).
Unpaired Student t-test were performed to define a P value between the pencyclovir cream and the acyclovir cream. A P value of less than 0.05 was considered statistically significant.
After the 24 h skin exposure time creams were washed off from the skin and the acyclovir cream had 6-fold more drug remaining in the washed-off cream than the penciclovir cream, with 245 μg/cm2 versus 40 μg/cm2, respectively (not shown). These values represent the amount of unabsorbed drug.
Comparison of the amount of antiviral drug found in the various skin compartments.
Penciclovir cream (P)
Acyclovir cream (A)
Dermis (residual stripped skin)
Permeation through the skin (receptor phase)
Penciclovir cream (P)
Acyclovir cream (A)
% applied dose
Dermis (residual stripped skin)
Permeation through the skin (receptor phase)
After 24 h the amount of penciclovir permeated through the skin from the 1% cream was 3.4 fold more than acyclovir from the 5% cream (0.41 vs. 0.12 μg/cm2) (Table 1), leading to a flux of respectively 17 ng/cm2/h and 5 ng/cm2/h as depicted in Figure 2B.
When the results were compare at equivalent dose 16.7 fold more penciclovir from the 1% cream permeated through the skin than acyclovir, which was mainly limited to the superficial skin layer. This difference show a trends toward statistical difference (P = 0.06; Figure 1C and Table 1). Significantly more penciclovir were detected in deeper strips such as strip 2 (P = 0.002) and pooled strips (P = 0.04). The difference between penciclovir and acyclovir found in the dermis were close to statistical significance (P = 0.06; Figure 1C and Table 1). Permeation through the excised human skin reached 3.3% of the applied dose for penciclovir and 0.2% for acyclovir (Table 1).
Measurement of in vitro permeation across the split thickness of human skin enables the evaluation of the passive diffusion of the molecule into and across the skin to a solute reservoir, which simulates the capillaries of the dermis. Several factors influence the skin permeation among which are the release of the drug from the formulation, its penetration into the stratum corneum layers (10–20 μm) and its diffusion through the stratum corneum into the various epidermis layers (100 μm) and the dermis (1200 μm) to reach the circulation, as simulated by the fluid in the reservoir.
When compared at an equivalent dose penciclovir from the cream has the trend to have a higher transcutaneous delivery than acyclovir. These results indicate a more effective release of penciclovir from the cream and across the stratum corneum. Both formulations contain approximately 40% of propylene glycol (Acyclovir, 5% Zovirax contains 40% and penciclovir 1% Pencivir contains 43%) which is widely use as a co-solvent and penetration enhancer . This fatty alcohol, which diffuses well through the stratum corneum  might alter the properties of this membrane leading to improved drug distribution especially for penciclovir, while further permeation into the receptor fluid might be impaired for acyclovir. This difference between these structurally related polar molecules might be explained by the formulation itself together with the presence of hydrophobic region in the acyclovir structure as determined by the molecular modelling. This moiety may interact with hydrophobic structure in the stratum corneum preventing further penetration. It has been reported that increased lipophilicity is used to reduce systemic absorption, which was reported for the corticosteroids . The hydrophilic feature of penciclovir as shown in Figure 3 might not react with hydrophobic structures, thus allowing penciclovir to be freely "drawn" by the solvent between the corneocytes of the stratum corneum within the hydrophilic region, constituting the paracellular pathway [13, 22].
These results give evidence that basal cells were removed during the tape stripping and were found mostly in the deeper epidermal layer. Thus, concentrations per area of penciclovir in pooled strips were converted into concentration by volume with an estimate of epidermal depth of 100 μm , which yielded a 60 fold higher concentration than the in vitro inhibitory effect on HSV-1 with IC50 of 0.5–0.8 μg/ml as reported by Weinberg . This suggests penciclovir might be highly efficient in reducing the viral load in the infected cells of the basal epidermal layers when compared to the surface of epidermis represented by the stratum corneum.
It is questionable whether the observed concentration differences found between the two drugs at the different skin layers might be due to the different intracellular half lives of acyclovir (0.7–1 h) and penciclovir (10–20 h) [25–27]. As the excised skin was frozen before use this tissue might not be viable lacking metabolism and enzymatic activity . Consequently, this excludes under experimental conditions of the present study that viral thymidine kinase could be active and could phosphorylate both drugs which would be retained in cells . In the future it could be of interest to perform the study with fresh and viable excised skin infected or not by HSV-1 to evaluate the contribution of the viral enzymatic activity on the drug bioavailability into the deeper epidermal layers where the target cells are present.
In this in vitro model the passive diffusion of two hydrophilic drugs from two comparable formulations were studied showing both creams delivered the drug in deeper epidermal skin layers where target basal cells were localized as determined by the expression of the specific keratin 5 protein. Molecular modelling enabled for the first time to reveal difference between acyclovir and penciclovir on the surface properties. This observation might support that penciclovir has the tendency to have a higher paracellular passage through the stratum corneum resulting in a tendency to reach higher concentration in deeper epidermal layers.
As permeability properties of the stratum corneum remained unchanged in non viable human skin the findings of the present study might be extrapolated to in use condition. By applying the cream at the prodormal stage, when skin appears undamaged it can be postulated the drug would be delivered at the level of basal cells where the HSV-1 virus could be found in case of cold sore infection.
The authors wish to thank Dr U. Hasler (Fondation pour Recherches Médicales, University of Geneva, Switzerland) for performing the western blot assay.
- Gold D, Corey L: Acyclovir Prophylaxis for Herpes Simplex Virus Infection. Antimicrob Agents Chemother 1987, 31: 361–367.PubMedPubMed CentralView Article
- Hamuy R, Berman B: Treatment of Herpes Simplex Virus Infections With Topical Antiviral Agents. Eur J Dermatol 1998, 8: 310–319.PubMed
- Raborn GW, Martel AY, Lassonde M, Lewis MA, Boon R, Spruance SL: Effective Treatment of Herpes Simplex Labialis With Penciclovir Cream: Combined Results of Two Trials. J Am Den Assoc 2002, 133: 303–309.View Article
- Spruance SL, Rea TL, Thoming C, Tucker R, Saltzman R, Boon R: Penciclovir Cream for the Treatment of Herpes Simplex Labialis. A Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial. Topical Penciclovir Collaborative Study Group. JAMA 1997, 277: 1374–1379. 10.1001/jama.277.17.1374PubMedView Article
- Visalli RJ, Courtney RJ, Meyers C: Infection and Replication of Herpes Simplex Virus Type 1 in an Organotypic Epithelial Culture System. Virology 1997, 230: 236–243. 10.1006/viro.1997.8484PubMedView Article
- Jarvis CA, McGuigan C, Heard CM: In Vitro Delivery of Novel, Highly Potent Anti-Varicella Zoster Virus Nucleoside Analogues to Their Target Site in the. Pharm Res 2004,21(6):914–919. 10.1023/B:PHAM.0000029277.60760.43PubMedView Article
- Marzulli FN: Barriers to Skin Penetration. J Invest Dermatol 1962, 39: 387–393.PubMedView Article
- Kleymann G: Novel Agents and Strategies to Treat Herpes Simplex Virus Infections. Expert Opin Investig Drugs 2003, 12: 165–183. 10.1517/135437220.127.116.11PubMedView Article
- Wagner H, Kostka KH, Lehr CM, Schaefer UF: Human Skin Penetration of Flufenamic Acid: in Vivo/in Vitro Correlation (Deeper Skin Layers) for Skin Samples From the Same Subject. J Invest Dermatol 2002, 118: 540–544. 10.1046/j.0022-202x.2001.01688.xPubMedView Article
- Guy RH, Carlstrom EM, Bucks DA, Hinz RS, Maibach HI: Percutaneous Penetration of Nicotinates: in Vivo and in Vitro Measurements. J Pharm Sci 1986, 75: 968–972. 10.1002/jps.2600751012PubMedView Article
- Wagner H, Kostka KH, Lehr CM, Schaefer UF: Drug Distribution in Human Skin Using Two Different in Vitro Test Systems: Comparison With in Vivo Data. Pharm Res 2000, 17: 1475–1481. 10.1023/A:1007648807195PubMedView Article
- Franz TJ: Kinetics of Cutaneous Drug Penetration. Int J Dermatol 1983, 22: 499–505. 10.1111/j.1365-4362.1983.tb02187.xPubMedView Article
- Moser K, Kriwet K, Naik A, Kalia YN, Guy RH: Passive Skin Penetration Enhancement and Its Quantification in Vitro. Eur J Pharm Biopharm 2001, 52: 103–112. 10.1016/S0939-6411(01)00166-7PubMedView Article
- Rolland A: Localization of Drugs in the Skin. In In Vitro Percutaneous Absorption: principles, Fundamentals and Applications. Edited by: Bronaugh RL, Maibach HI. CRC Press Boca Raton; 1991:137–156.
- Schaefer H, Redelmeier TE: Structure and Dynamics of the skin barrier. Skin barrier: Principles of Percutaneous Absorption. Karger Basel 1996, 1–42.
- Bronaugh RL, Stewart RF, Simon M: Methods for in Vitro Percutaneous Absorption Studies. VII: Use of Excised Human Skin. J Pharm Sci 1986, 75: 1094–1097. 10.1002/jps.2600751115PubMedView Article
- Skin Absorption – In Vitro Method. OECD [Organisation for Economic Cooperation and Development]. Guideline 428 2004.
- Ertl P, Muhlbacher J, Rohde B, Selzer P: Web-Based Cheminformatics and Molecular Property Prediction Tools Supporting Drug Design and Development at Novartis. SAR QSAR Environ Res 2003, 4: 321–328. 10.1080/10629360310001673917View Article
- Surber C, Schwarb FP, Smith EW: Tape-Stripping Technique. J Toxicol Cut & Ocular Toxicol 2001, 20: 461–474. 10.1081/CUS-120001870View Article
- Williams AC, Barry BW: Penetration Enhancers. Adv Drug Deliv Rev 2004, 56: 603–618. 10.1016/j.addr.2003.10.025PubMedView Article
- Brazzini B, Pimpinelli N: New and Established Topical Corticosteroids in Dermatology: Clinical Pharmacology and Therapeutic Use. Am J Clin Dermatol 2002, 3: 47–58. 10.2165/00128071-200203010-00005PubMedView Article
- Menon GK, Elias PM: Morphologic Basis for a Pore-Pathway in Mammalian Stratum Corneum. Skin Pharmacol 1997, 10: 235–246. 10.1159/000211511PubMedView Article
- Sandt J, Roguet R, Cohen C, Esdaile D, Ponec M, Corsini E, Barker C, Fusenig N, Liebsch M, Benford D, de Brugerolles de Fraissinette A, Fartasch M: The Use of Human keratinocytes and Human Skin Models for Predicting Skin Irritation. Atla 1999, 27: 723–743.PubMed
- Weinberg A, Bate BJ, Masters HB, Schneider SA, Clark JC, Wren CG, Allaman JA, Levin MJ: In Vitro Activities of Penciclovir and Acyclovir Against Herpes Simplex Virus Types 1 and 2. Antimicrob Agents Chemother 1992, 36: 2037–2038.PubMedPubMed CentralView Article
- Earnshaw DL, Bacon TH, Darlison SJ, Edmonds K, Perkins RM, Vere Hodge R: A Mode of Antiviral Action of Penciclovir in MRC-5 Cells Infected With Herpes Simplex Virus Type 1 (HSV-1), HSV-2, and Varicella-Zoster Virus. Antimicrob Agents Chemother 1992, 36: 2747–2757.PubMedPubMed CentralView Article
- Hayden FG: Antimicrobial agents-antiviral agents (nonretroviral). Tenth edition. Mc Graw Hill Medical Publishing Division New-York, Chicago, San Francisco, Lisbon, London, Madrid, Mexico City, New Delhi, San Juan, Seoul, Singapore, Sidney, Toronto; 2001.
- Reusser P: Herpesvirus Resistance to Antiviral Drugs: a Review of the Mechanisms, Clinical Importance and Therapeutic Options. J Hosp Infect 1996, 33: 235–248. 10.1016/S0195-6701(96)90010-9PubMedView Article
- Wester RC, Christoffel J, Hartway T, Poblete N, Maibach HI, Forsell J: Human cadaver skin viability for in vitro percutaneous absorption: storage and detrimental effects of heat-separation and freezing. Pharm Res 1998, 15: 82–84. 10.1023/A:1011904921318PubMedView Article
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-5945/9/3/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.